BioPharma Reporter

JUNE 24, 2021

Iksuda Therapeutics, a developer of a new generation of antibody drug conjugates (ADCs), has expanded its research collaboration and license agreement with LegoChem Biosciences Inc (LCB).

DNA 55

DNA Licensing Licensing Antibody 55

The Pharma Data

DECEMBER 3, 2020

TWO: 4162) announced today that it has entered into a Collaboration and License Agreement with UK-based Sentinel Oncology Limited for advancing the new drug development of SOL-578 , a Checkpoint Kinase 1 (Chk1) inhibitor, under which PharmaEngine will fund the IND enabling studies for SOL-578. TAIPEI , Dec.

Licensing 52

Licensing Licensing Bioavailability DNA 52

Drug Discovery Today

JULY 7, 2022

Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapiesAgreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercializationAccess (..)

Licensing 40

Licensing Licensing Gene Manufacturing 40

pharmaphorum

JUNE 27, 2022

Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks’ treatment to below the lower limit of detection in people with chronic hepatitis B, raising hopes that it could offer permanent cure, allowing safe termination of antiviral therapy.

DNA 124

DNA Drugs Sales Licensing 124

pharmaphorum

NOVEMBER 5, 2021

There have also been come concerns about the risk of birth defects with molnupiravir due to its mechanism of action that can lead to DNA changes, and Pfizer has been quick to point out that it has found no evidence of “mutagenic DNA interactions” with its protease inhibitor.

DNA 116

DNA Contract Manufacturing HR Manufacturing 116

pharmaphorum

JANUARY 5, 2023

The company develops mRNA therapeutics and vaccines , and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portfolio.

Gene Sequencing 97

Gene Sequencing DNA Vaccine Vaccination 97

pharmaphorum

FEBRUARY 19, 2021

Once someone is infected with HIV it stays with them for life thanks to the retrovirus’s ability to inject its DNA code into the host. Excision wants to take its lead therapy candidate, EBT-101, into a phase 1/2 clinical trial in patients with chronic HIV infection with the proceeds from this latest financing round.

Gene Editing 105

Gene Editing In-Vivo DNA In-Vitro 105

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” About INOVIO’s DNA Medicines Platform. mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

pharmaphorum

APRIL 22, 2022

Astellas also revealed today that it is terminating the development of ASP2390, a DNA vaccine for house dust mite-induced allergic rhinitis, and GITR agonist antibody ASP1951 for cancer – both in early-stage clinical development – along with DMD gene therapies AT702, AT751 and AT753.

Gene Therapy 105

Gene Therapy Gene DNA Development 105

pharmaphorum

APRIL 7, 2021

In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 Last week, it licensed a series of fibroblast activation protein (FAP) targeting agents from iTheranostics that can be used to image and potentially to treat tumours. It’s also providing research funding.

DNA 52

DNA Licensing Licensing Gene Therapy 52

pharmaphorum

OCTOBER 3, 2022

Translarna was the first licensed treatment for DMD which addresses the loss of dystrophin. A gene therapy, it permits the body to read over the DNA mutation and still continue to produce dystrophin. Eventually, they will need assistance with breathing.

Gene Therapy 98

Gene Therapy Gene FDA Approval DNA 98

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects.

Antibody 130

Antibody Hormones DNA Licensing 130

The Pharma Data

MARCH 30, 2021

Targeted radioligand therapy is a type of precision medicine combining two key elements: a targeting compound, or ligand, and a radioactive isotope, causing DNA damage that inhibits tumor growth and replication. We believe this technology has the potential to transform many patients’ lives.”.

Protein 52

Protein Licensing Licensing Containment 52

BioPharma Reporter

JULY 20, 2023

Twist Bioscience, a biotech company manufacturing synthetic DNA, and Cancer Research Horizons, the innovation engine at the core of Cancer Research UK, have announced an agreement under which Cancer Research Horizons will license the entire Twist Biopharma Solutions Library of Libraries.

Research 40

Research DNA Engineer Licensing 40

XTalks

MAY 22, 2023

Related: 5 Food Companies Working With Precision Fermentation Technology How Pairwise Leverages CRISPR Technology CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is a gene-editing technique that can be used to alter the DNA of cells to enhance certain characteristics or reduce less desirable ones.

Branding 98

Branding Gene Editing DNA Production 98

BioTech 365

OCTOBER 15, 2020

Aegis Life is launched to pursue US-based development and commercialization of SARS-CoV-2 vaccine using the Entos Fusogenix technology and to support manufacturing and distribution of millions of DNA vaccine doses globally Aegis Life signs a license agreement with Nature Technology … Continue reading →

Vaccine 40

Vaccine Vaccination DNA Licensing 40

BioTech 365

OCTOBER 15, 2020

Aegis Life is launched to pursue US-based development and commercialization of SARS-CoV-2 vaccine using the Entos Fusogenix technology and to support manufacturing and distribution of millions of DNA vaccine doses globally Aegis Life signs a license agreement with Nature Technology … Continue reading →

Vaccine 40

Vaccine Vaccination DNA Licensing 40

XTalks

DECEMBER 13, 2023

Xoma’s unique approach involves acquiring future economic interests tied to pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotech companies. It is now progressing towards the submission of a Biologics License Application (BLA) by the end of 2023. million, compared to $1.1

Genetics 111

Genetics Vaccination Vaccine DNA 111

Pharmaceutical Technology

FEBRUARY 3, 2023

The established method for this process is a triple transfection using three different DNA plasmids. This is really what has been very challenging for upscaling viral vector production and what leads some companies that have in-licensed projects with a huge amount of viral vector to slightly panic about future production,” she says.

Genome 244

Genome Genomics Medicine Gene Therapy 244

pharmaphorum

AUGUST 28, 2020

In the phase 2a trial, GSK3228836 was able to reduce two biomarkers of chronic HBV infection – hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA – compared to placebo after four weeks treatment. Meanwhile, five of 12 previously-untreated patients had 2-log (90%) or a greater reduction in HBV DNA.

Drugs 52

Drugs DNA Licensing Licensing 52

pharmaphorum

MARCH 8, 2021

billion for the company in direct sales as well as another $460 million in alliance revenue from Merck, which licensed co-marketing rights to the product in 2017. GSK has told NICE it is not seeking approval of Zejula for hormone-relapsed metastatic prostate cancer with DNA-repair anomalies in Europe, so its appraisal has been suspended.

Hormones 98

Hormones Marketing Trials DNA 98

pharmaphorum

JANUARY 30, 2022

Top of the list was Oxford Nanopore’s stellar debut on the London Stock Exchange at the end of September, raising £350 million and propelling the vale of the DNA sequencing specialist up towards the £5 billion mark. The post Offshore warning as UK biotech investment rises sharply in 2021 appeared first on.

Life Science 98

Life Science Allergies DNA Licensing 98

XTalks

JUNE 20, 2022

Alnylam’s Onpattro was its first licensed and approved RNAi therapy for ATTR polyneuropathy. XTALKS WEBINAR: Liquid Biopsy Workflow Optimization for Improved Assay Sensitivity and Multianalyte Applications of Cell-Free RNA, DNA and CTCs. These abnormalities can lead to progressive heart failure and death.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

pharmaphorum

NOVEMBER 9, 2022

In the latest results from the 457-patient B-Clear study, published in the New England Journal of Medicine, bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to 10% of participants with chronic HBV infection.

Drugs 98

Drugs Sales Trials DNA 98

Delveinsight

DECEMBER 17, 2020

Following that hypothesis, scientists designed oral inhibitors, which could target mitochondrial DNA (mtDNA). Instead of directly targeting existing mitochondria, the team went after mitochondrial DNA transcription that is vital to the formation of new mitochondria and the production of energy. in 2017.

Gene Therapy 96

Gene Therapy Gene DNA Genetics 96

Roots Analysis

FEBRUARY 27, 2024

Currently, product licensing agreements, technology licensing agreements, research and development agreements and clinical trial agreements are the common types of partnerships inked by developers that are currently focused on the development of ADCs pipeline. In nature, they are made by a group of bacteria known as actinomycetes.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

pharmaphorum

DECEMBER 21, 2020

Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code. The rest is history – Pfizer stepped in and licensed the technology, choosing the most promising of four potential mRNA vaccines from BioNTech.

Vaccine 111

Vaccine Vaccination Doctor Doctors 111

pharmaphorum

SEPTEMBER 24, 2021

The Galleri test will look at the DNA in each patient’s blood to determine if any comes from tumours, which shed cell-free nucleic acids (cfDNA), carrying signals specific to cancer. The UK health service partner with Silicon Valley-based healthcare company Grail in a randomised control trial involving up to 140,000 volunteers.

Clinical Trials 120

Clinical Trials Clinical Trials Trials Licensing 120

Delveinsight

DECEMBER 1, 2020

BASE10 Collaborates with DNA Link for COVID-19 Antibody Test Research. US-based BASE10 Genetics and Korean firm DNA Link announced a collaboration on a research project to appraise the usability of the DNA Link’s antibody test, AccuFind COVID-19 IgG, in a healthcare setting. CABOMETYX is already approved in the U.S.

Antibody 52

Antibody DNA Clinical Trials Clinical Trials 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Its primary focus is on oncology, cardiovascular, immunology, and fibrotic therapeutic projects.

Antibody 130

Antibody DNA Genome Genomics 130

pharmaphorum

MAY 7, 2021

Founded by Nobel prize winner Emmanuelle Charpentier, CRISPR Therapeutics has been at the forefront of the gene editing technology and has refined it to the point where it can be used to accurately edit DNA to correct genetic conditions or modify cells to fight disease.

Gene Editing 52

Gene Editing Gene Genetic Engineering DNA 52

pharmaphorum

MAY 24, 2022

Monkeypox is considered less likely to mutate quickly because it is a DNA virus rather than an RNA virus like influenza or COVID-19. There’s also a licensed antiviral drug for monkeypox. It also stressed there is no evidence that a viral mutation is responsible for the unusual pattern of infections.

Vaccine 95

Vaccine Vaccination RNA DNA 95

The Pharma Data

DECEMBER 2, 2020

Results show the protocol demonstrated a 30Gb+ yield of long DNA reads raw data of an E. The FMv8 protocol introduces a needle-aspirate-based, cell-resuspension step prior to cell lysis that boosts DNA recovery. based Horizon Discovery Group granted a license to China’s Sanyou Biopharmaceuticals Co. in Mainland China.

Drugs 52

Drugs Gene Editing Genome Genomics 52

pharmaphorum

JULY 5, 2021

Swedish private equity group EQT has swooped on Parexel just two weeks after selling plasmid DNA producer Aldevron – whose technology is used to make the Moderna COVID-19 vaccine – to medical equipment producer Danaher Corp for $9.6

Clinical Trials 64

Clinical Trials Clinical Trials Trials Regulation 64

XTalks

APRIL 23, 2021

dMMR occurs when a cell is unable to repair errors made during cellular replication, owing to mutations in DNA mismatch repair genes such as MLH1 or MLH2 , resulting in high-frequency microsatellite instability (H-MSI). The immunotherapy received approval as a monotherapy based on GSK’s Biologics License Application (BLA).

FDA Approval 105

FDA Approval Trials Antibody DNA 105

pharmaphorum

FEBRUARY 5, 2021

DNA testing company 23andMe has signed a deal to merge with a ‘blank cheque’ company set up by Virgin billionaire Sir Richard Branson as a shortcut to a public listing. 23andMe – which will be valued at around $3.5 The merger is due to complete in the second quarter, and will give 23andMe a listing on the NYSE with the ticker symbol “ME”.

Genetics 52

Genetics DNA Life Science Clinical Trials 52

pharmaphorum

AUGUST 27, 2020

Today researchers are attaching only a portion of the DNA or mRNA of the virus to a harmless molecule. Because they are relatively new, these techniques have not yet yielded licensed products for human use. Conventional vaccines introduce an inactivated sample of a disease to patients with the aim of stimulating an immune response.

Vaccination 122

Vaccination Vaccine Life Science Clinical Trials 122